Total Payments
$2,673
2024 Payments
$1,337
Companies
15
Transactions
131
Medicare Patients
990
Medicare Billing
$127,280
Payment Breakdown by Category
Food & Beverage$2,673 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,673 | 131 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $535.74 | 51 | $0 (2024) |
| Novo Nordisk Inc | $464.60 | 26 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $371.45 | 9 | $0 (2024) |
| Abbott Laboratories | $202.65 | 6 | $0 (2024) |
| Amgen Inc. | $201.24 | 8 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $194.82 | 5 | $0 (2024) |
| ABBVIE INC. | $190.01 | 5 | $0 (2024) |
| Allergan, Inc. | $145.09 | 2 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $136.53 | 5 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $65.47 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,337 | 61 | Bayer Healthcare Pharmaceuticals Inc. ($334.40) |
| 2023 | $1,004 | 60 | Lilly USA, LLC ($269.78) |
| 2019 | $155.85 | 3 | Allergan, Inc. ($125.00) |
| 2018 | $55.00 | 3 | Merck Sharp & Dohme Corporation ($34.91) |
| 2017 | $121.25 | 4 | AstraZeneca Pharmaceuticals LP ($74.05) |
All Payment Transactions
131 individual payment records from CMS Open Payments — Page 3 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/07/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: Inflammation | ||||||
| 03/01/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: NEUROSCIENCE | ||||||
| 02/23/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: Respiratory | ||||||
| 02/20/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $11.28 | General |
| Category: Diabetes | ||||||
| 02/16/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/12/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: Diabetes | ||||||
| 02/01/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $9.74 | General |
| Category: Diabetes | ||||||
| 02/01/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $2.45 | General |
| Category: Diabetes | ||||||
| 01/27/2024 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $20.90 | General |
| 01/06/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: Diabetes | ||||||
| 01/05/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $3.35 | General |
| Category: Diabetes | ||||||
| 12/18/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: Gastroenterology | ||||||
| 12/12/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $12.93 | General |
| Category: Inflammation | ||||||
| 12/08/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/01/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Diabetes | ||||||
| 11/11/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: Diabetes | ||||||
| 11/08/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $6.85 | General |
| Category: Diabetes | ||||||
| 11/08/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $0.48 | General |
| Category: Diabetes | ||||||
| 11/03/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: NEUROSCIENCE | ||||||
| 11/02/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: Inflammation | ||||||
| 10/30/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $21.39 | General |
| Category: Diabetes | ||||||
| 10/21/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: Cardio-renal | ||||||
| 10/13/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: NEUROSCIENCE | ||||||
| 10/13/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $9.05 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 296 | 613 | $113,658 | $38,989 |
| 2022 | 4 | 214 | 511 | $58,681 | $27,537 |
| 2021 | 2 | 133 | 607 | $59,300 | $28,180 |
| 2020 | 7 | 347 | 840 | $101,987 | $32,573 |
Total Patients
990
Total Services
2,571
Medicare Billing
$127,280
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 95 | 262 | $63,434 | $22,141 | 34.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 77 | 185 | $34,692 | $11,640 | 33.6% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 32 | 32 | $5,664 | $2,232 | 39.4% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 12 | 35 | $3,080 | $1,058 | 34.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 28 | 45 | $3,465 | $857.15 | 24.7% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 13 | 14 | $1,554 | $557.34 | 35.9% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 27 | 27 | $1,080 | $474.93 | 44.0% |
| 81003 | Automated urinalysis test | Office | 2023 | 12 | 13 | $689.00 | $28.60 | 4.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 66 | 163 | $22,331 | $12,469 | 55.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 73 | 203 | $20,300 | $7,891 | 38.9% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2022 | 23 | 23 | $6,900 | $3,694 | 53.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 52 | 122 | $9,150 | $3,483 | 38.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 107 | 551 | $55,100 | $26,599 | 48.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 26 | 56 | $4,200 | $1,582 | 37.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 146 | 461 | $46,100 | $15,589 | 33.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 16 | 45 | $10,395 | $3,639 | 35.0% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 84 | 187 | $14,025 | $3,333 | 23.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 53 | 60 | $8,220 | $2,869 | 34.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 13 | 51 | $9,945 | $2,862 | 28.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 18 | 18 | $8,262 | $2,788 | 33.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 17 | 18 | $5,040 | $1,493 | 29.6% |
About Dr. Robert Sepulveda, M.D
Dr. Robert Sepulveda, M.D is a Internal Medicine healthcare provider based in Weslaco, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1366473258.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Sepulveda, M.D has received a total of $2,673 in payments from pharmaceutical and medical device companies, with $1,337 received in 2024. These payments were reported across 131 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($2,673).
As a Medicare-enrolled provider, Sepulveda has provided services to 990 Medicare beneficiaries, totaling 2,571 services with total Medicare billing of $127,280. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Weslaco, TX
- Active Since 07/06/2006
- Last Updated 09/19/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1366473258
Products in Payments
- MOUNJARO (Drug) $386.78
- Kerendia (Drug) $371.45
- Ozempic (Drug) $212.24
- Rybelsus (Drug) $209.87
- XARELTO (Drug) $194.82
- QULIPTA (Drug) $153.76
- FREESTYLE LIBRE (Device) $132.25
- AVYCAZ (Drug) $125.00
- FARXIGA (Drug) $121.71
- Prolia (Biological) $97.43
- Otezla (Drug) $92.04
- JARDIANCE (Drug) $76.46
- FREESTYLE LIBRE 3 (Device) $70.40
- Cologuard Collection Kit (Device) $49.60
- ELIQUIS (Drug) $49.03
- VRAYLAR (Drug) $36.25
- TRULICITY (Drug) $35.20
- JANUVIA (Drug) $34.91
- Dexcom G6 Transmitter (Medical Supply) $34.32
- Wegovy (Drug) $28.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Weslaco
Hector Amaya Chinchilla, M.d, M.D
Internal Medicine — Payments: $5,736
Internal Medicine $5,736
Dionisio Calvo
Internal Medicine — Payments: $4,184
Internal Medicine $4,184
Dr. Claudia Pierson, M.d, M.D
Internal Medicine — Payments: $3,969
Internal Medicine $3,969
Pedro Penalo, Md, MD
Internal Medicine — Payments: $3,559
Internal Medicine $3,559
Jesus Rodriguez Hernandez, M.d, M.D
Internal Medicine — Payments: $2,593
Internal Medicine $2,593
Dr. Amrit Sraow, M.d, M.D
Internal Medicine — Payments: $1,916
Internal Medicine $1,916